LIVE NEWS UPDATE

Indian Pharma Live News

Latest pharmaceutical, regulatory, research and business developments from across India's pharma industry.

LIVE
🇮🇳 INDIAN NEWS
India FoundationIndia Foreign Trade and the Strategic Challenge of Chinese APIs Dependency - India Foundation pharma.economictimes.indiatimes.comMankind licenses Lung cancer drug ensartinib from China’s Betta Pharmaceuticals - pharma.economictimes.indiatimes.com BW Healthcare WorldBiodeal Pharmaceuticals Gets CDSCO Approval For India's First Midazolam Nasal Spray - BW Healthcare World Business StandardIndian drugmakers sharpen oncology focus with US approvals, new deals - Business Standard drugscontrol.orgIndian Pharmaceutical Industry Faces Stringent IPR Scrutiny: High Courts Protect Finecure's Website, Ban Z-CONTIN Nitroglycerin Tablets and Restrain Generic NO-CINV - drugscontrol.org IMARC GroupHPMC Capsule Manufacturing Plant Setup Cost in India - IMARC Group MMJDailyIndia: Himachal Pradesh issues cannabis cultivation licences to three pharma firms and 24 farmers - MMJDaily The Indian ExpressColumn | Paradox of drug choice: Why India prefers branded illusion over cheap generics - The Indian Express Medical DialoguesIndia Mulls Allowing MNCs to Conduct First-in-Human Phase I Clinical Trials - Medical Dialogues BioSpectrum IndiaBiodeal Pharma receives New Drug Permission from CDSCO for indigenously developed Midazolam Nasal Spray - BioSpectrum India India FoundationIndia Foreign Trade and the Strategic Challenge of Chinese APIs Dependency - India Foundation pharma.economictimes.indiatimes.comMankind licenses Lung cancer drug ensartinib from China’s Betta Pharmaceuticals - pharma.economictimes.indiatimes.com BW Healthcare WorldBiodeal Pharmaceuticals Gets CDSCO Approval For India's First Midazolam Nasal Spray - BW Healthcare World Business StandardIndian drugmakers sharpen oncology focus with US approvals, new deals - Business Standard drugscontrol.orgIndian Pharmaceutical Industry Faces Stringent IPR Scrutiny: High Courts Protect Finecure's Website, Ban Z-CONTIN Nitroglycerin Tablets and Restrain Generic NO-CINV - drugscontrol.org IMARC GroupHPMC Capsule Manufacturing Plant Setup Cost in India - IMARC Group MMJDailyIndia: Himachal Pradesh issues cannabis cultivation licences to three pharma firms and 24 farmers - MMJDaily The Indian ExpressColumn | Paradox of drug choice: Why India prefers branded illusion over cheap generics - The Indian Express Medical DialoguesIndia Mulls Allowing MNCs to Conduct First-in-Human Phase I Clinical Trials - Medical Dialogues BioSpectrum IndiaBiodeal Pharma receives New Drug Permission from CDSCO for indigenously developed Midazolam Nasal Spray - BioSpectrum India
LIVE UPDATES

Top Global Pharma News

Latest pharmaceutical, biotech and regulatory developments from leading global sources.

LIVE
TOP NEWS
Fierce Pharma Regulatory tracker: Lilly beats Novo to land China's 1st oral GLP-1 weight loss nod - Fierce Pharma The Pharma Letter What FDA and EMA now accept from real-world data - The Pharma Letter RAPS Recon: FDA approves generic lenacapavir intended for lower income countries; EMA to review Lundbeck's Deanxit for reported serious side effects - RAPS European Medicines Agency (EMA) EMA and FDA set common principles for AI in medicine development - European Medicines Agency (EMA) BioPharm International FDA and EMA Requirements Converge for Cell and Gene Therapy CMC, but GMP Gaps Persist - BioPharm International Fierce Biotech The 2026 Cell Therapy Regulatory Landscape: Aligning CMC Strategy with FDA and EMA Expectations - Fierce Biotech Business Wire Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T) - Business Wire HDBuzz SOM3355 Moves Toward Phase 3 as Both EMA and FDA Signal Support - HDBuzz EurekAlert! ARDD 2026 brings global pharma, FDA leaders and longevity science pioneers to Harvard October 1–3 - EurekAlert! Fierce Pharma Regulatory tracker: FDA starts review of Sandoz's generic tirzepatide - Fierce Pharma Fierce Pharma Regulatory tracker: Lilly beats Novo to land China's 1st oral GLP-1 weight loss nod - Fierce Pharma The Pharma Letter What FDA and EMA now accept from real-world data - The Pharma Letter RAPS Recon: FDA approves generic lenacapavir intended for lower income countries; EMA to review Lundbeck's Deanxit for reported serious side effects - RAPS European Medicines Agency (EMA) EMA and FDA set common principles for AI in medicine development - European Medicines Agency (EMA) BioPharm International FDA and EMA Requirements Converge for Cell and Gene Therapy CMC, but GMP Gaps Persist - BioPharm International Fierce Biotech The 2026 Cell Therapy Regulatory Landscape: Aligning CMC Strategy with FDA and EMA Expectations - Fierce Biotech Business Wire Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T) - Business Wire HDBuzz SOM3355 Moves Toward Phase 3 as Both EMA and FDA Signal Support - HDBuzz EurekAlert! ARDD 2026 brings global pharma, FDA leaders and longevity science pioneers to Harvard October 1–3 - EurekAlert! Fierce Pharma Regulatory tracker: FDA starts review of Sandoz's generic tirzepatide - Fierce Pharma

Addvertisement

Editorial

Rare disease drug reviews need a credible reset
Editorial
Current Article

Rare disease drug reviews need a credible reset

Author: Editorial Board
Published: October 21, 2026 • 6:44 pm
The FDA’s rare-disease review initiative could make drug development more predictable and responsive to patients’ unmet needs. VoP’s view: Greater regulatory flexibility must come with rigorous evidence, transparent decisions, and strong safety and quality standards.
Read Full Article →
History

Expert Opinion

AI Assisted Contamination Assessment in Pharmaceutical Microbiology
Expert Opinion
Current Article

AI Assisted Contamination Assessment in Pharmaceutical Microbiology

Author: Mrs. Reeta Nauriyal
Published: October 10, 2026 • 2:38 pm
This article explores how artificial intelligence can support contamination assessment, colony detection, and environmental monitoring in pharmaceutical microbiology. It highlights the need for validated methods, reliable data, and microbiologist oversight to strengthen quality control and protect product quality.
Read Full Article →
History
History 1
No history article available
More Expert Opinion articles will appear here automatically when published.
History 2
No history article available
More Expert Opinion articles will appear here automatically when published.
History 3
No history article available
More Expert Opinion articles will appear here automatically when published.

Guest Article

History
History 1
No history article available
More Guest Article articles will appear here automatically when published.
History 2
No history article available
More Guest Article articles will appear here automatically when published.
History 3
No history article available
More Guest Article articles will appear here automatically when published.

Other

Pharmaceutical Billing and HSN Classification
Other
Current Article

Pharmaceutical Billing and HSN Classification

Author: Mr. Deepak Kumar
Published: October 10, 2026 • 3:58 pm
This article examines common HSN classification and billing problems in the pharmaceutical industry, including GST mismatches, pricing errors, and expired-stock returns. It outlines practical solutions through verified product records, controlled tax updates, accurate invoicing, and regular reconciliation.
Read Full Article →
History
History 1
No history article available
More Other articles will appear here automatically when published.
History 2
No history article available
More Other articles will appear here automatically when published.
History 3
No history article available
More Other articles will appear here automatically when published.

Top-Category News Display

Vacancies In Pharma

The Story Behind Voice of Pharma

01

But its stories are scattered.

Voice of Pharma brings them together. We unify global and domestic pharmaceutical intelligence into a single curated destination.

Research Innovation Startups Regulation Journals Tech
Scattered pharma information unified
02

We don’t compete for every story.

We connect the stories, respect the original sources, and ensure that every authentic voice in the industry gets the recognition it deserves.

Connecting voices and respecting sources
1000+
Curated Intelligence
Global & domestic sources tracked daily
24+
Industry Pillars
Research, Startups, Regulation, Policy, Journals, Tech
100%
Original Attribution
Integrity & source respect guaranteed

Meet Our Experts

Julia Naroz
Front Face

Julia Naroz

Front Face
Bharadhawaj Mukesh
News & Media Coverage

Bharadhawaj Mukesh

News & Media Coverage
Amrit Dubey
Camera & Mice Expert

Amrit Dubey

Camera & Mice Expert
Mrs. Priya Devi
Editor in Chief Digital Media

Mrs. Priya Devi

Editor in Chief Digital Media
Mrs. Shalini Bisht
Pharma & Consultant

Mrs. Shalini Bisht

Pharma & Consultant
Mr. Roopesh Sachan
Behind the Curtain

Mr. Roopesh Sachan

Behind the Curtain
Voice of Pharma ecosystem
Discover • Connect • Appreciate • Credit • Create

One Pharma World. Many Voices. One Place.

[vop_live_chat]